Deferoxamine (DFO) binds ferric (Fe [+++] ) ions to its three hydroxamic groups forming ferrioxamine. This forms a stable, water-soluble compound that is readily excreted by the kidneys. DFO does not appear to chelate other trace metals (except aluminum) or electrolytes in clinically significant quantities.
Deracoxib is indicated for the treatment of post-operative pain (higher dose, 7 day maximum), and for the treatment of pain and inflammation associated with osteoarthritis (lower dose, ongoing dosing) in dogs. Like piroxicam, deracoxib is of interest in adjunctive treatment of transitional cell carcinoma of the bladder; investigations into this use are ongoing.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
D0776 與 D0201 是同一去鐵胺有效成分；D0201 是唯一已複核臨床條目。D0776 必須導向 D0201，不得計算、處方或另行提供第二套劑量、安全、交互作用、監測、產品或飼主資料。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。
renal